Cancer-Killing virus and immune drug combo tested in advanced tumors – study halted early

NCT ID NCT06063317

Terminated Disease control Sponsor: Imugene Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new treatment for adults with advanced solid tumors that had not responded to standard therapies. The treatment combined a cancer-killing virus (onCARlytics) with an immune-boosting drug (blinatumomab), given either into the tumor or through a vein. The study aimed to check safety and find the best dose, but it was terminated early, so only limited safety data were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: onCARlytics (CF33-CD19) and blinatumomab
What this could lead to: If successful, this approach could point toward a new way to treat advanced solid tumors by using a virus to target cancer cells and an immune therapy to boost the body's attack.
What could go wrong: This was a very early (Phase 1) study that was terminated, so results are limited. The combination may cause serious side effects, and it is unknown if it will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bites and Stings metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Emory Winship Cancer Institute

Atlanta, Georgia, 30322, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Northwestern

Chicago, Illinois, 60208, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14203, United States
University of Cincinnati

Cincinnati, Ohio, 45219, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.